Literature DB >> 17453514

Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation.

E D Rappeport1, A Loft, A K Berthelsen, P von der Recke, P Noergaard Larsen, A Mellon Mogensen, A Wettergren, A Rasmussen, J Hillingsoe, P Kirkegaard, C Thomsen.   

Abstract

BACKGROUND: The choice of imaging before liver surgery is debated regarding the use of magnetic resonance (MR) imaging, computed tomography (CT), and positron emission tomography (PET). No studies have compared contrast-enhanced PET/CT with superparamagnetic iron oxide (SPIO)-enhanced MR imaging.
PURPOSE: To compare PET/CT with superparamagnetic iron oxide (SPIO)-enhanced MR imaging, PET, and CT in the detection of liver metastases (LM) and extrahepatic tumor from colorectal cancer (CRC).
MATERIAL AND METHODS: Thirty-five patients with suspected LM underwent PET/CT with a contrast-enhanced CT protocol and SPIO-enhanced MR imaging. Readers independently analyzed images from MR imaging, PET/CT, and the CT part and PET part of the PET/CT study. Imaging findings were compared with surgical and histological findings.
RESULTS: Lesion-by-lesion sensitivity and accuracy for liver lesions was 54% and 77% for PET alone, 66% and 83% for PET/CT, 82% and 82% for SPIO-enhanced MR imaging, and 89% and 77% for CT alone, respectively. CT and SPIO-enhanced MR imaging were less specific but significantly more sensitive than PET (P<0.0001). For extrahepatic tumor, sensitivity and specificity was 83% and 96% for PET/CT and 58% and 87% for CT, respectively.
CONCLUSION: CT and SPIO-enhanced MR imaging are more sensitive but less specific than PET in the detection of LM. PET/CT can detect more patients with extrahepatic tumor than CT alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17453514     DOI: 10.1080/02841850701294560

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  30 in total

1.  Assessment of liver metastases from colorectal adenocarcinoma following chemotherapy: SPIO-MRI versus FDG-PET/CT.

Authors:  L Bacigalupo; S Aufort; M C Eberlé; E Assenat; M Ychou; B Gallix
Journal:  Radiol Med       Date:  2010-06-23       Impact factor: 3.469

2.  Use of computed tomography in the management of colorectal cancer.

Authors:  Cher Heng Tan; Revathy Iyer
Journal:  World J Radiol       Date:  2010-05-28

3.  Can PET-CT with FDG replace contrast enhanced CT for imaging of liver metastases?

Authors:  Ludwig G Strauss; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12       Impact factor: 9.236

4.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.

Authors:  V O Chan; J P Das; J F Gerstenmaier; J Geoghegan; R G Gibney; C D Collins; S J Skehan; D E Malone
Journal:  Ir J Med Sci       Date:  2012-03-17       Impact factor: 1.568

Review 5.  Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review.

Authors:  Anna Margherita Maffione; Egesta Lopci; Christina Bluemel; Francesco Giammarile; Ken Herrmann; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-16       Impact factor: 9.236

6.  Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer.

Authors:  Jeong Won Lee; Seok-Ki Kim; Sang Mi Lee; Seung Hwan Moon; Tae-Sung Kim
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

Review 7.  Imaging diagnosis of colorectal liver metastases.

Authors:  Ling-Hui Xu; San-Jun Cai; Guo-Xiang Cai; Wei-Jun Peng
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

8.  Contrast-enhanced magnetic resonance imaging with a novel nano-size contrast agent for the clinical diagnosis of patients with lung cancer.

Authors:  Jianwei Gao; Lei Li; Xia Liu; Rui Guo; Bin Zhao
Journal:  Exp Ther Med       Date:  2018-04-30       Impact factor: 2.447

9.  The diagnostic challenge of mediastinal sarcoidosis accompanying esophageal cancer.

Authors:  Matthias Schauer; Joerg Theisen
Journal:  World J Surg Oncol       Date:  2010-03-12       Impact factor: 2.754

Review 10.  Non-invasive diagnostic imaging of colorectal liver metastases.

Authors:  Pier Paolo Mainenti; Federica Romano; Laura Pizzuti; Sabrina Segreto; Giovanni Storto; Lorenzo Mannelli; Massimo Imbriaco; Luigi Camera; Simone Maurea
Journal:  World J Radiol       Date:  2015-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.